Notably, high mesothelin levels have been associated with chemoresistance and poor survival in epithelial ovarian carcinoma, leading to ongoing clinical trials evaluating the safety and efficacy of mesothelin-targeted drugs in platinum-resistant ovarian cancer [63,64,65]. Here, MSLN is linked to ovarian cancer.